No abstract

These results indicate that the two formulations of dexamethasone are bioequivalent and thus may be prescribed interchangeably.

Aim: To compare the bioavailability of two cetirizine tablet (10 mg) formulations (Zyrtec® from UCB Pharma, Spain as a reference formulation and Ryvel® from Novell Pharmaceutical Laboratories, Indonesia as a test formulation. Material and methods: The study was conducted according an open, randomized, two-period crossover design with a 1-week washout period. Eighteen volunteers participated and all completed the study successfully. Blood samples were obtained prior to dosing and at 0.25, 0.5, 1, 2, 3, 5, 8, 12, 24 and 30 hours after drug administration. Plasma concentrations of cetirizine were monitored using high performance liquid chromatography over a period of 30 hours after administration. The pharmacokinetics parameter AUC 0-30h , AUC 0-∞ and C max were tested for bioequivalence after log-transformation of data and ratios of T max were evaluated non-parametrically. Result: The point estimates and 90% confidence intervals for AUC 0-30h, AUC 0-∞ and C max were 108.23% (101.90-114.95%), 108.11% (101.91-114.68%) and 99.71% (90.18-110.25%) respectively, satisfying the bioequivalence criteria of the European Committee for Proprietary Medicinal Products an the US Food and Drug Administration guidelines. Conclusion: These results indicate that two medications of cetirizine are bioequivalent and, thus, may be prescribed interchangeably.

These results indicate that two formulations of estazolam are bioequivalent and, thus, may be prescribed interchangeably.